Manuel Litchman, M.D.

President, Chief Executive Officer and Director

Dr. Litchman has served as President and Chief Executive Officer and has been a member of Mustang’s Board of Directors since April 2017. Dr. Litchman joined Mustang from Arvinas, LLC, where he served as President and Chief Executive Officer. While at Arvinas, Dr. Litchman oversaw the advancement of the company’s pipeline of protein-degradation therapeutics for the treatment of cancers and other diseases toward Investigational New Drug applications, as well as the execution of multi-target discovery collaborations with Merck and Genentech. Prior to Arvinas, Dr. Litchman spent more than 18 years with Novartis Pharmaceuticals Corporation, where he held positions of increasing responsibility related to the development of Novartis’ oncology pipeline. Most recently, Dr. Litchman served as Senior Vice President and Executive Global Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration with the University of Pennsylvania investigating chimeric antigen receptor modified T cells (CAR Ts) directed against CD19 on B cell malignancies. Prior to the CTL019 collaboration, Dr. Litchman served as Novartis’ Vice President and Head, Oncology Business Development & Licensing. Earlier in his career, Dr. Litchman was a senior equity analyst at Ursus Capital and directed oncology / immunology clinical research at Hoffmann-La Roche Inc. Dr. Litchman received his M.D. from Yale University School of Medicine, and his B.A. from Princeton University. He completed his internal medicine residency and hematology-oncology fellowship at New York-Presbyterian Hospital / Weill Cornell Medical Center.

Greg Furrow, M.S., FRQA

Chief Quality Officer

Greg Furrow joined Mustang Bio in January 2019 as head of Quality. He is responsible for leading the Quality Organization inclusive of Clinical Quality Assurance, Manufacturing Quality Assurance, Quality Control Chemistry, Microbiology and Raw Material, and Quality Systems in compliance with Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMP), Good Clinical Practices (GCP), Good Laboratory Practices (GLP), and current ICH requirements.  Previously, Greg was Vice President of Quality and Compliance at Southern Research, an independent, 501(c)(3) nonprofit, scientific research organization where he was responsible for Quality Assurance, Bio-safety, Environmental Health and Safety, ISO-9000 Quality Systems Management, Information Technology (IT), Human Resources (HR), Export Control and Government Security.  Prior to Southern Research, Greg was Vice President of Quality and Regulatory Compliance at WIL research (now part of Charles River), a global CRO supporting the pharmaceutical, chemical and agrochemical industries where he was responsible for global Quality Assurance (GLP, GCP and cGMP) and Environmental Health and Safety.  Greg received his B.S. and M.S. from the University of Maryland at College Park. He is a past president of the Society of Quality Assurance, an honorary life Fellow of the Research Quality Association, a lecturer in Purdue University’s Regulatory and Quality Compliance graduate program and he is the EPA industry representative to the OECD GLP discussion group.

James Murphy, B.A.

Ad interim Chief Financial Officer

James Murphy joined Mustang Bio as Ad interim Chief Financial Officer in January 2024.  Mr. Murphy has served as a consultant to several companies through Danforth, an advisory firm that provides operational and strategic support services to life science companies. During Mr. Murphy’s tenure at Danforth, he has served as interim Chief Financial Officer in both public and private life science companies since 2012. Prior to joining Danforth, Mr. Murphy served as the Chief Financial Officer at OxiGene, Inc., a publicly traded biotechnology company, from February 2004 to April 2012. Mr. Murphy began his career in this life science sector in 1990 when he joined Sepracor Inc., a publicly traded specialty pharmaceutical and device company. Mr. Murphy received his B.A. in economics and accounting from the College of the Holy Cross.